Navigation Links
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Date:8/22/2007

SOMERSET, N.J., Aug. 22 /PRNewswire-FirstCall/ - Alfacell Corporation (Nasdaq: ACEL) today announced that a paper published in the International Journal of Oncology (2007; Vol. 31, Issue 3: 663-669) reports that ONCONASE(R) substantially decreases reactive oxygen intermediates (ROI) in normal cell types and tumor cell lines. The observed antioxidant activity of ONCONASE may be important to its cytotoxic effect on cancer cells and mechanistic synergism with other anti-cancer agents.

The pre-clinical in vitro research conducted by Alfacell and researchers at New York Medical College demonstrated that treatment of cells in cultures with ONCONASE reduced intracellular oxidative stress by suppressing ROI generation and promoting their degradation. The anti-oxidative function of ONCONASE may be an important element of its antiproliferative/cytotoxic activity towards cancer cells and a possible mechanism of its well-documented synergism with other anti-cancer agents. Additionally, the data indicate that ONCONASE has a propensity to reverse the generation of ROI from asbestos exposure in mesothelial cells. The Company is currently conducting a Phase IIIb human clinical trial of ONCONASE for the treatment of patients suffering from unresectable malignant mesothelioma.

"The data further confirm the cytotoxic effect of ONCONASE on cancer cells," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "ONCONASE's therapeutic potential is broad. This study shows that ONCONASE has potential not only for cancer, but for conditions pathogenetically related to oxidative stress or the activation of NF-kappa B, such as inflammation, autoimmune diseases, atherosclerosis and septic shock."

About ONCONASE(R)
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is proud ... Vision, Innovation, and Leadership has been awarded to Stuart ... an individual who has had a significant impact on the ... several decades. "I am honored to receive the ... Ph.D., CEO of PTC Therapeutics, Inc. "When I founded PTC ...
(Date:11/21/2014)...  Edwards Lifesciences Corporation (NYSE: EW ), ... and hemodynamic monitoring, announced today that it will increase ... strong launch of Edwards Lifesciences Foundation,s new charitable initiative, ... global communities where its employees live and work. ... exceed $8 million, including more than $7 million in ...
(Date:11/21/2014)... Telbec/ - KLOX Technologies Inc. ("KLOX" or the "Company") ... Todd Martensen has been hired to ... Chief Commercial Officer, to oversee KLOX,s commercial launch of ... the treatment of chronic and other hard-to-heal wounds, as ... Europe . Mr. Martensen, a seasoned ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4
... , , ROCKVILLE, Md. , ... ) announced today that the company has decided to discontinue ... ROVI Pharmaceuticals ( Madrid : ROVI) to develop Novavax,s virus-like-particle ... .  This decision is due to the companies, inability to ...
... , SALT LAKE CITY , Feb. ... Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory systems, ... Company  received a NASDAQ Staff Deficiency Letter indicating that the ... Rule requires the Company to have at least three independent ...
Cached Medicine Technology:Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605 2
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... Karen Ignagni, President and CEO of America,s Health Insurance ... the President,s budget:"Today,s budget submission sends a signal to ... prioritizing health care. We applaud the President for ... resources to put our nation on a path towards ...
... SEO Online PR & Marketing Consultancy, is pleased to announce the ... successful Industry Directory, offering free listings to relevant specialist industries. ... ... B2B, SEO Online PR & Marketing Consultancy , is pleased ...
... N.C., Feb. 26 Arbor Pharmaceuticals, a specialty,pharmaceutical ... the company has launched XYLAREX - a first-in-class ... media (middle ear,infections). XYLAREX is a novel ... the number of ear infections children experience. ...
... Feb. 26 A lawsuit was filed today by ... who contracted salmonella poisoning,after eating at a Blueberry Hill ... child was hospitalized for three days as a result ... Cook County Department of Health,after the Communicable Disease Unit ...
... groups nationwide to receive National Autism Conference DVD ... Association (NAA) today announced its receipt of a ... (CWF) to disseminate DVD sets of complete presentations ... organizations throughout the United States, U.S. territories, and ...
... to continuing multi-pronged effort to raise awarenessWASHINGTON, Feb. 26 ... for a Drug-Free America offers some promising news regarding ... According to the 20th annual Partnership Attitude Tracking Survey ... about drugs and alcohol, an increased number of teens ...
Cached Medicine News:Health News:AHIP Statement on the President's Budget 2Health News:Simply Marcomms Launch New Specialist Online Industry Directories 2Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2Health News:National Autism Association Announces American Legion Child Welfare Grant for Autism Outreach 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 3
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... primary known naturally-occurring stimulant of red blood ... human EPO is 18.2 kDa. Due to ... an estimated molecular mass of ~30.5 kDa. ... unique structure, the EPO receptor bears some ...
... Alpha Fetoprotein (AFP) is a 68 kDa protein, ... the fetal liver and yolk sac [1]. ... weeks gestation, and production rates reach 19-26 g/min ... and estimates of total fetal AFP continue to ...
Medicine Products: